[go: up one dir, main page]

MX2008014273A - Procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion. - Google Patents

Procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion.

Info

Publication number
MX2008014273A
MX2008014273A MX2008014273A MX2008014273A MX2008014273A MX 2008014273 A MX2008014273 A MX 2008014273A MX 2008014273 A MX2008014273 A MX 2008014273A MX 2008014273 A MX2008014273 A MX 2008014273A MX 2008014273 A MX2008014273 A MX 2008014273A
Authority
MX
Mexico
Prior art keywords
high efficiency
human albumin
obtaining high
detoxification therapy
efficiency human
Prior art date
Application number
MX2008014273A
Other languages
English (en)
Inventor
Nieto Juan Ignacio Jorquera
Debart Pere Ristol
Rierola Montserrat Costa
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39167937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008014273(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of MX2008014273A publication Critical patent/MX2008014273A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procedimiento de obtención de albúmina humana de alta eficacia para su uso en terapia de detoxificación. El procedimiento comprende a) una primera diálisis (diafiltración); b) la estabilización de la solución con NaCl y al menos un aminoácido; c) el calentamiento de la solución; d) una segunda diálisis (diafiltración).
MX2008014273A 2007-11-12 2008-11-07 Procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion. MX2008014273A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702983A ES2294976B1 (es) 2007-11-12 2007-11-12 "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".

Publications (1)

Publication Number Publication Date
MX2008014273A true MX2008014273A (es) 2009-05-11

Family

ID=39167937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008014273A MX2008014273A (es) 2007-11-12 2008-11-07 Procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion.

Country Status (15)

Country Link
US (2) US8088416B2 (es)
EP (1) EP2072056B1 (es)
JP (2) JP2009137947A (es)
CN (1) CN101492493B (es)
AR (1) AR069220A1 (es)
AU (1) AU2008243225B2 (es)
BR (1) BRPI0805167B8 (es)
CA (1) CA2643508C (es)
CL (1) CL2008003357A1 (es)
ES (2) ES2294976B1 (es)
HU (1) HUE026991T2 (es)
MX (1) MX2008014273A (es)
NZ (1) NZ572652A (es)
PL (1) PL2072056T3 (es)
RU (1) RU2424822C2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP6247210B2 (ja) * 2011-07-05 2017-12-13 アルブミディクス アクティーゼルスカブ アルブミン製剤及び用途
WO2013125932A1 (ru) * 2012-02-22 2013-08-29 Даугавпилсский Университет Метод определения структурных и функциональных свойств альбумина плазмы крови
AU2013205138B2 (en) * 2012-08-09 2015-06-25 Grifols, S.A. Caprylate Viral Deactivation
CN103087184B (zh) * 2013-01-14 2014-04-02 山西康宝生物制品股份有限公司 人血白蛋白制品中激肽释放酶原激活剂的控制方法
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EP3500588A1 (en) 2016-08-17 2019-06-26 Boehringer Ingelheim International GmbH Process for the preparation of highly concentrated liquid formulations containing biomolecules
BR112019003172A2 (pt) * 2016-08-18 2019-05-28 Alkahest Inc frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4267210A1 (en) 2020-12-28 2023-11-01 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
CH720224B1 (de) * 2023-08-18 2024-05-31 Csl Behring Ag Verfahren zur Sterilfiltration albuminhaltiger wässriger Lösungen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5128727A (es) 1974-09-04 1976-03-11 Canon Kk
US4043997A (en) * 1976-05-28 1977-08-23 Cutter Laboratories, Inc. Method for isolating albumin using insoluble supports coupled to a dye
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
JP3554796B2 (ja) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
FR2672604B1 (fr) 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
US5368555A (en) * 1992-12-29 1994-11-29 Hepatix, Inc. Organ support system
AUPM388494A0 (en) * 1994-02-16 1994-03-10 Csl Limited Process for removing endotoxins
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
ES2107390B1 (es) 1996-01-30 1998-07-01 Grupo Grifolls S A Procedimiento para la preparacion de albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
ES2103236B1 (es) * 1996-01-30 1998-04-16 Grifols Grupo Sa Albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
AT403989B (de) * 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
US5919907A (en) * 1997-12-22 1999-07-06 Shanbrom Technologies Llc Preparation and utilization of a novel sterile albumin
DE19831061A1 (de) * 1998-07-10 2000-01-13 Rotkreuzstiftung Zentrallab Herstellung von Proteinpräparationen mit verringertem Aggregatgehalt
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
ATE249847T1 (de) * 1999-06-15 2003-10-15 Bbi Bioseq Inc Schnelle tieftemperatur-drucksterilisation und impfstoffherstellung
EP1565207B1 (en) * 2002-11-25 2006-04-12 Octapharma AG Prekallikrein depleted plasma derived albumin fraction
ATE362376T1 (de) 2003-02-13 2007-06-15 Octapharma Ag Verfahren zur herstellung einer albuminlösung
US20040217055A1 (en) * 2003-03-12 2004-11-04 Elmar Kraus Use of recombinant albumin in dialysis after liver failure
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
WO2006066595A2 (en) * 2004-12-22 2006-06-29 Novozymes A/S Recombinant production of serum albumin
DE102005023155A1 (de) * 2005-05-13 2006-11-16 Albutec Gmbh Albuminlösung
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".

Also Published As

Publication number Publication date
HK1129401A1 (en) 2009-11-27
RU2008144318A (ru) 2010-05-20
AU2008243225A1 (en) 2009-05-28
RU2424822C2 (ru) 2011-07-27
EP2072056B1 (en) 2016-02-24
US8231599B2 (en) 2012-07-31
HUE026991T2 (en) 2016-08-29
AU2008243225B2 (en) 2011-09-08
CN101492493A (zh) 2009-07-29
ES2294976B1 (es) 2008-12-16
CN101492493B (zh) 2013-05-29
US20110137283A1 (en) 2011-06-09
BRPI0805167B8 (pt) 2021-05-25
JP5744959B2 (ja) 2015-07-08
AR069220A1 (es) 2010-01-06
ES2564310T3 (es) 2016-03-21
JP2013173767A (ja) 2013-09-05
US8088416B2 (en) 2012-01-03
CA2643508A1 (en) 2009-05-12
ES2294976A1 (es) 2008-04-01
CA2643508C (en) 2013-06-11
BRPI0805167A2 (pt) 2009-07-14
CL2008003357A1 (es) 2011-01-07
EP2072056A1 (en) 2009-06-24
PL2072056T3 (pl) 2016-06-30
NZ572652A (en) 2010-03-26
US20090181102A1 (en) 2009-07-16
JP2009137947A (ja) 2009-06-25
BRPI0805167B1 (pt) 2019-01-02

Similar Documents

Publication Publication Date Title
MX2008014273A (es) Procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion.
UA105210C2 (ru) Противораковая вакцина и ее применение
NZ603200A (en) Peptides and their use
NO2017003I1 (no) Kobicistat eller farmasøytisk akseptabelt salt derav og tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
WO2008098212A3 (en) Extended release formulations of glucagon and other peptides and proteins
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
WO2008093165A3 (en) The use of pgil ohgosaccharyltransferase for o-glycosylating proteins
EP4488289A3 (en) Long-acting coagulation factors and uses thereof
UA95446C2 (ru) Мутаци в генах oas1
PH12012501203A1 (en) Combination of theobromine with a decongestant and its use for the treatment of cough
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
GB0818080D0 (en) Immunogenic peptides
GB2466744A (en) Holding fixture with a plate having male and/or female attaching means for holding identical unit; method of manufacturing a structure made of welded units.
Podichetty et al. Re: Oleske DM, Lavender SA, Andersson GB, et al. Are back supports plus education more effective than education alone in promoting recovery from low back pain? Results from a randomized clinical trial. Spine 2007; 32: 2050-7
UA50803U (ru) Способ лечения острых инфекционных вирусных заболеваний у больных с хронической патологией органов пищеварения
UA33147U (ru) Способ коррекции морфофункционального состояния печени у больных хроническим панкреатитом
UA39274U (ru) Способ формирования глоточно-пищеводного соустья у больных раком гортани после ларингэктомии
UA27727U (en) Method for combined treatment of herpes virus infection in newborns
UA33198U (ru) Способ коррекции иммунокомплексного спектра крови у больных соматоформными депрессивными расстройствами
UA34801U (ru) Способ коррекции состояния макрофагальной фагоцитирующей системы у больных туберкулезом легких
UA47996U (ru) Способ лечения дистрофических заболеваний глаза
UA48591U (ru) Способ лечения разлитых флегмон челюстно-лицевого участка
UA62538U (ru) Способ комплексного лечения острого деструктивного панкреатита
UA62258U (ru) Способ лечения ожогов глаз

Legal Events

Date Code Title Description
FG Grant or registration